Anthra Bonefos advisory committee
Executive Summary
Anthra's Bonefos (clodronate sodium) will be reviewed by FDA's Oncologic Drugs Advisory Committee on the afternoon of Dec. 4. Anthra is seeking approval for the bisphosphonate (NDA 21-326) in the reduction of skeletal complications of bone metastases in patients with breast cancer. The meeting will be held at the Holiday Inn in Silver Spring, Md. The oncology committee will consider Guilford's NDA (20-637/S-016) for Gliadel Wafer (polifeprosan 20/carmustine implant) for first-line malignant glioma in the morning (1"The Pink Sheet" Oct. 15, In Brief)